AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19228745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine alone (arm A)
Number of subjects: 115
Study 19228745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine + GM-CSF (arm B)
Number of subjects: 115
Study 19228745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine + IFN-alpha2b (arm C)
Number of subjects: 115
Study 19228745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine + IFN-alpha2b + GM-CSF (arm D)
Number of subjects: 115
Study 19228745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine immune response
Number of subjects: 115
Study 19228745 — intervention group
Group type: COMPARATOR
Intervention: No immune response
Number of subjects: 115
Study 16806095 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 16
Study 16806095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12775857 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT plus counselling (6 week course of NRT and 20 minute counselling intervention)
Number of subjects: 274
Study 12775857 — intervention group
Group type: COMPARATOR
Intervention: Counselling alone (20 minute intervention with written materials)
Number of subjects: 274
Study 12775857 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional advice at admission)
Number of subjects: 274
Study 12775857 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT plus counselling
Number of subjects: 274
Study 12775857 — intervention group
Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 274
Study 12775857 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274
Study 12775857 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT plus counselling, Counselling alone, Usual care
Number of subjects: 274
Study 10684783 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 87
Study 10684783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 10684783 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.34, 0.68, and 1.02 g/kg)
Number of subjects: 87
Study 9361639 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) including visual examination, finger pads for palpation, and using the 3 middle fingers.
Number of subjects: 220
Study 9361639 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting 1 of the 3 BSE components.
Number of subjects: 220
Study 9361639 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting 2 of the 3 BSE components.
Number of subjects: 220
Study 9361639 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting all 3 BSE components.
Number of subjects: 220
Study 8364943 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% cream
Number of subjects: 143
Study 8364943 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 143
Study 8364943 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% cream (long-term phase)
Number of subjects: 143
Study 3313841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza‐Po
Number of subjects: 64
Study 3313841 — intervention group
Group type: COMPARATOR
Intervention: CsA‐Po
Number of subjects: 64
Study 3313841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza‐Po to CsA‐Po
Number of subjects: 64
Study 3313841 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐Po to Aza‐Po
Number of subjects: 64
Study 29897249 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once-daily)
Number of subjects: 54
Study 29897249 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide alone
Number of subjects: 54
Study 25903686 — intervention group
Group type: EXPERIMENTAL
Intervention: Single debridement (SD) at postoperative week 1
Number of subjects: 62
Study 25903686 — intervention group
Group type: COMPARATOR
Intervention: Frequent debridement (FD) at postoperative weeks 1, 2 and 4
Number of subjects: 62
Study 24495204 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples treatment
Number of subjects: 93
Study 24495204 — intervention group
Group type: COMPARATOR
Intervention: Individuals treatment
Number of subjects: 93
Study 23539727 — intervention group
Group type: EXPERIMENTAL
Intervention: Desiccated thyroid extract (DTE)
Number of subjects: 70
Study 23539727 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine (L-T₄)
Number of subjects: 70
Study 23539727 — intervention group
Group type: COMPARATOR
Intervention: Neither (no preference)
Number of subjects: 70
Study 16192761 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25969 (8 mg/kg)
Number of subjects: 29
Study 16192761 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25969 (0.1-8.0 mg/kg)
Number of subjects: 29
Study 16192761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12905476 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg every 6 weeks after induction phase)
Number of subjects: 65
Study 12905476 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Infliximab (12-week crossover)
Number of subjects: 65
Study 12905476 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 65
Study 12905476 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Infliximab
Number of subjects: 65
Study 9797093 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler blood flow measurements and serum VEGF concentrations measured at various stages of the IVF cycle.
Number of subjects: 107
Study 7892316 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid expansion starting 1 week postoperatively on a daily basis; expansion period of 14 days.
Number of subjects: 28
Study 7892316 — intervention group
Group type: COMPARATOR
Intervention: Slow expansion starting after 2 weeks, once each week; expansion period of 37 days.
Number of subjects: 28
Study 2293600 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid diet
Number of subjects: 6
Study 2293600 — intervention group
Group type: COMPARATOR
Intervention: Solid diet
Number of subjects: 6
Study 204624 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized aftercare clinic
Number of subjects: 30
Study 204624 — intervention group
Group type: COMPARATOR
Intervention: Private psychiatrists
Number of subjects: 30
Study 29779802 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feeds (10‐20 ml/kg/day) starting 4‐6 hours after surgery
Number of subjects: 15
Study 29779802 — intervention group
Group type: COMPARATOR
Intervention: NPO (no feeding) for 48 hours after surgery
Number of subjects: 15
Study 27809219 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat/refined grain diet
Number of subjects: 51
Study 27809219 — intervention group
Group type: COMPARATOR
Intervention: Dairy/chicken/nuts/whole grain diet
Number of subjects: 51
Study 24743444 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264
Study 24743444 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264
Study 21749488 — intervention group
Group type: EXPERIMENTAL
Intervention: Teff bread (TB)
Number of subjects: 58
Study 21749488 — intervention group
Group type: COMPARATOR
Intervention: Control bread (CB)
Number of subjects: 58
Study 21749488 — intervention group
Group type: EXPERIMENTAL
Intervention: TB+level 2 phytase (TB+P2)
Number of subjects: 58
Study 21749488 — intervention group
Group type: EXPERIMENTAL
Intervention: TB+level 1 phytase (TB+P1)
Number of subjects: 58
Study 21749488 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement containing 10 mg of ferrous sulphate
Number of subjects: 58
Study 20008056 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg intravaginal misoprostol
Number of subjects: 120
Study 20008056 — intervention group
Group type: COMPARATOR
Intervention: 50 microg intravaginal misoprostol
Number of subjects: 120
Study 18445928 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable membrane coated with 25% doxycycline
Number of subjects: 24
Study 18445928 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable membrane alone
Number of subjects: 24
Study 15777442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron sulphate 80 mg daily
Number of subjects: 52
Study 15777442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11949775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (nutritionally balanced amino acid mixtures without tryptophan)
Number of subjects: 0
Study 11949775 — intervention group
Group type: COMPARATOR
Intervention: Control (nutritionally balanced amino acid mixtures with tryptophan)
Number of subjects: 0
Study 10529070 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 114
Study 10529070 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 114
Study 7547822 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal infusion of 100 g/l Intralipid (8.36 kJ/min)
Number of subjects: 13
Study 7547822 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (9 g NaCl/l)
Number of subjects: 13
Study 7547822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (fat energy:CHO, 64:18)
Number of subjects: 13
Study 7547822 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (fat energy:CHO, 7:76)
Number of subjects: 13
Study 2389909 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 0.2 mg inhaled three times a day for 2 months
Number of subjects: 31
Study 2389909 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaled three times a day for 2 months
Number of subjects: 31
Study 2389909 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) treatment withheld after second antigen provocation
Number of subjects: 31
Study 6108460 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breast milk
Number of subjects: 24
Study 6108460 — intervention group
Group type: COMPARATOR
Intervention: Low-fat breast milk
Number of subjects: 24
Study 30459103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 30459103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28408372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB)
Number of subjects: 12
Study 28408372 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 25590523 — intervention group
Group type: EXPERIMENTAL
Intervention: sTM levels at enrollment (highest quartile > 14 ng/mL vs. lowest quartile < 7 ng/mL)
Number of subjects: 1103
Study 25590523 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndecan‐1 levels at enrollment (> 240 vs. < 70 ng/mL)
Number of subjects: 1103
Study 24024727 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 32
Study 24024727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (ropinirole 0.25 mg/d)
Number of subjects: 32
Study 24024727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21338496 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (378 mg/day) and theanine (210 mg/day)
Number of subjects: 200
Study 21338496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 19390340 — intervention group
Group type: EXPERIMENTAL
Intervention: PACER (patient-assisted computerized education for recipients of ICDs)
Number of subjects: 30
Study 19390340 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 17889242 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITNs)
Number of subjects: 3500
Study 17889242 — intervention group
Group type: COMPARATOR
Intervention: Control (no ITN use)
Number of subjects: 3500
Study 15462694 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐Stocking (Venotrain ulcertec) applied for at least eight hours per day for up to 12 weeks
Number of subjects: 134
Study 15462694 — intervention group
Group type: COMPARATOR
Intervention: Compression bandages applied for at least eight hours per day for up to 12 weeks
Number of subjects: 134
Study 15462694 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐Stocking
Number of subjects: 134
Study 15462694 — intervention group
Group type: COMPARATOR
Intervention: Compression bandages
Number of subjects: 134
Study 15462694 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐Stocking and Compression bandages
Number of subjects: 134
Study 11444446 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 56
Study 11444446 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 56
Study 11444446 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 56
Study 11444446 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56
Study 9566478 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Detoxification (HD) programme
Number of subjects: 95
Study 9566478 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI) strategies
Number of subjects: 95
Study 8040671 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with cisplatin and fluorouracil (5‐FU) followed by radiation therapy
Number of subjects: 166
Study 8040671 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery followed by radiation therapy
Number of subjects: 166
Study 2494586 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 1
Study 2494586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 4880259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (monthly sessions and daily autohypnosis for one year)
Number of subjects: 252
Study 4880259 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises (control group)
Number of subjects: 252
Study 4880259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 252
Study 4880259 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises
Number of subjects: 252
Study 4880259 — intervention group
Group type: COMPARATOR
Intervention: Hypnosis and Breathing exercises
Number of subjects: 252
Study 31740723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 10
Study 31740723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30001225 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 3799
Study 30001225 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 3799
Study 30001225 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 3799
Study 28000127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering treatment (target SBP <140 mmHg within 1 hour)
Number of subjects: 2839
Study 28000127 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure-lowering treatment (target SBP <180 mmHg)
Number of subjects: 2839
Study 26362235 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 60
Study 26362235 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (Steroid) injection
Number of subjects: 60
Study 23193218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 139
Study 23193218 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting list group)
Number of subjects: 139
Study 21981559 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 21981559 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study 18280832 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy measures (feeding modifications, positioning, tobacco smoke avoidance)
Number of subjects: 40
Study 16556888 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched related donor (MRD) allogeneic stem cell transplantation (SCT)
Number of subjects: 1508
Study 16556888 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched unrelated donor (MUD) allogeneic SCT
Number of subjects: 1508
Study 16556888 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 1508
Study 16556888 — intervention group
Group type: COMPARATOR
Intervention: Consolidation/maintenance chemotherapy
Number of subjects: 1508
Study 16556888 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 1508
Study 12681111 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group (WG)
Number of subjects: 47
Study 12681111 — intervention group
Group type: COMPARATOR
Intervention: Air group (AG)
Number of subjects: 47
Study 12681111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 11194431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (200 mg)
Number of subjects: 19
Study 11194431 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19
Study 8791948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d.
Number of subjects: 120
Study 8791948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus Amoxycillin 750 mg b.d. plus Clarithromycin 250 mg b.d.
Number of subjects: 120
Study 1620416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phosphocreatine administered after induction of anaesthesia, prior to cardiac arrest and after release of aortic cross-clamp
Number of subjects: 40
Study 1620416 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group A)
Number of subjects: 40
Study 6369215 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 38
Study 6369215 — intervention group
Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 38
Study 31804383 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance and aerobic exercise program
Number of subjects: 0
Study 28831717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief (3-day) course of levetiracetam (LEV)
Number of subjects: 84
Study 28831717 — intervention group
Group type: COMPARATOR
Intervention: Extended treatment (until hospital discharge)
Number of subjects: 84
Study 25934015 — intervention group
Group type: EXPERIMENTAL
Intervention: External counterpulsation (ECP) treatment, 35 daily 1 hour sessions
Number of subjects: 0
Study 25135383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 16
Study 25135383 — intervention group
Group type: COMPARATOR
Intervention: Continued Moderate Exercise (CON) for 12 weeks
Number of subjects: 16
Study 21880037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Number of subjects: 8
Study 21880037 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) emulsion, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Number of subjects: 8
Study 21880037 — intervention group
Group type: COMPARATOR
Intervention: Saline, administered intravenously at a rate of 0.2 g/kg BW/h for one hour on three consecutive days.
Number of subjects: 8
Study 20012445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent (INT)
Number of subjects: 46
Study 20012445 — intervention group
Group type: COMPARATOR
Intervention: Continuous (CNT)
Number of subjects: 46
Study 18062115 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil antimicrobial mouthrinse
Number of subjects: 37
Study 18062115 — intervention group
Group type: COMPARATOR
Intervention: Negative control mouthrinse
Number of subjects: 37
Study 16091026 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C
Number of subjects: 172
Study 16091026 — intervention group
Group type: COMPARATOR
Intervention: IGIV-SD
Number of subjects: 172
Study 12043860 — intervention group
Group type: EXPERIMENTAL
Intervention: System B continuous wave of condensation technique followed by Obtura II backfill
Number of subjects: 60
Study 12043860 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation technique
Number of subjects: 60
Study 9809934 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial contrast echocardiography (MCE) using bolus doses of a perfluorocarbon‐filled contrast agent (NC100100)
Number of subjects: 203
Study 9809934 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging in triggered mode
Number of subjects: 203
Study 9809934 — intervention group
Group type: EXPERIMENTAL
Intervention: MCE for detection of extensive defects
Number of subjects: 203
Study 9809934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of wall motion and MCE assessment
Number of subjects: 203
Study 9809934 — intervention group
Group type: EXPERIMENTAL
Intervention: MCE
Number of subjects: 203
Study 7661162 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with bismuth, metronidazole, and tetracycline (BMT) for 1 week
Number of subjects: 150
Study 7661162 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with sucralfate, metronidazole, and tetracycline (SMT) for 1 week
Number of subjects: 150
Study 7661162 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMT)
Number of subjects: 150
Study 7661162 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (SMT)
Number of subjects: 150
Study 2567768 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion followed by rinsing with water
Number of subjects: 0
Study 2567768 — intervention group
Group type: COMPARATOR
Intervention: Liquid soap and water
Number of subjects: 0
Study 769169 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 15
Study 769169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6990320 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimazine (sulphadiazine 410 mg and trimethoprim 90 mg 12-hourly)
Number of subjects: 120
Study 6990320 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (sulphamethoxazole 800 mg and trimethoprim 160 mg 12-hourly)
Number of subjects: 120
Study 6990320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphamethizole (1 g 8-hourly)
Number of subjects: 120
Study 31692308 — intervention group
Group type: EXPERIMENTAL
Intervention: OraQuick rapid test
Number of subjects: 1408
Study 31692308 — intervention group
Group type: EXPERIMENTAL
Intervention: Wantai rapid test
Number of subjects: 1408